title: Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers.
abstract: RSV can cause respiratory illness after SOT, yet preventive recommendations are lacking for this population. To ascertain current preventive practices against RSV disease in pediatric SOT candidates and recipients, a survey was developed. The survey was mailed to 108 SOT programs in the United States (liver, 42; heart, 28; lung, 11; intestinal, 25; and heart-lung, 2). Results were tabulated and analyzed using standard methods. Sixty-two percent (67/108) of surveys were completed. Forty-nine percent (33/67) of programs reported using RSV prophylaxis; palivizumab was used at 97% (32/33) of centers with 26 giving palivizumab to candidates and 27 to recipients. Prophylaxis was provided to infants aged 0-12 months by 27/29 (93%) of responding centers; 23/29 of centers extended its use to infants aged 0-24 months. Three centers gave prophylaxis to children between ages two and four yr and two centers for those over four yr. RSV prophylactic strategies, and in particular the use of palivizumab, are employed by almost 50% of responding pediatric SOT centers. Strategies varied at centers based on age and organ type. Data on RSV hospitalization and outcome are needed to refine approaches to RSV immunoprophylaxis in these high-risk patients.
authors.affiliation: Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA 15217, USA. marian.michaels@chp.edu
authors.forename: Marian G
authors.initials: MG
authors.lastname: Michaels
authors.forename: Monica
authors.initials: M
authors.lastname: Fonseca-Aten
authors.forename: Michael
authors.initials: M
authors.lastname: Green
authors.forename: Deborah
authors.initials: D
authors.lastname: Charsha-May
authors.forename: Barry
authors.initials: B
authors.lastname: Friedman
authors.forename: Mouin
authors.initials: M
authors.lastname: Seikaly
authors.forename: Pablo J
authors.initials: PJ
authors.lastname: Sánchez
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D019538:Health Care Surveys; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016377:Organ Transplantation; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab